Sanofi (NASDAQ:SNY) Shares Purchased by Bank of Stockton

Bank of Stockton raised its stake in Sanofi (NASDAQ:SNY) by 22.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,899 shares of the company’s stock after purchasing an additional 1,092 shares during the period. Bank of Stockton’s holdings in Sanofi were worth $340,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in SNY. Fifth Third Wealth Advisors LLC acquired a new stake in Sanofi in the first quarter valued at approximately $410,000. Register Financial Advisors LLC acquired a new stake in shares of Sanofi in the 1st quarter valued at $29,000. First Bank & Trust lifted its position in shares of Sanofi by 24.1% during the 1st quarter. First Bank & Trust now owns 35,855 shares of the company’s stock worth $1,743,000 after purchasing an additional 6,968 shares during the last quarter. BKM Wealth Management LLC grew its stake in shares of Sanofi by 74.3% during the first quarter. BKM Wealth Management LLC now owns 8,314 shares of the company’s stock worth $404,000 after purchasing an additional 3,543 shares in the last quarter. Finally, Park Place Capital Corp increased its holdings in Sanofi by 6.3% in the first quarter. Park Place Capital Corp now owns 9,068 shares of the company’s stock valued at $441,000 after buying an additional 534 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, Argus boosted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Sanofi presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Performance

Shares of Sanofi stock traded up $1.98 on Friday, hitting $54.03. The stock had a trading volume of 1,565,992 shares, compared to its average volume of 2,024,538. The stock has a market cap of $137.10 billion, a price-to-earnings ratio of 28.29, a P/E/G ratio of 1.40 and a beta of 0.60. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 52-week low of $42.63 and a 52-week high of $58.97. The company’s 50 day moving average price is $56.08 and its 200 day moving average price is $51.67.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.95 earnings per share. On average, research analysts anticipate that Sanofi will post 4.23 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.